PDCD1 and neoplasm: In this study of mice PD1-IL2v, an immunocytokine was engineered, combining CD8+ T-cell-targeting PD-1 binding with an IL-2 variant (IL2v) defective in binding to CD25, amplifying regulatory T lymphocytes while directly targeting the tumor.